LATERAL-FLOW IMMUNO-CHROMATOGRAPHIC ASSAY DEVICES

• US 20110076697A1
• Filed: 04/27/2010
• Published: 03/31/2011
• Est. Priority Date: 04/28/2009
• Status: Abandoned Application

• Current Assignee: Innovative Laboratory Technologies Incorporated
• Original Assignee: Innovative Laboratory Technologies Incorporated
• Inventors: Ruvinsky, Igor, Sklan, Ella
• Application Number:
  US12/768,706
• Publication Number:
  US 20110076697A1
• Time in Patent Office: Days
• US Class Current: 435/7.25
• CPC Class Codes: G01N 2333/4712 Muscle proteins, e.g. myosin, actin, protein
• CPC Class Codes: G01N 33/54386 Analytical elements
• CPC Class Codes: G01N 33/54388 based on lateral flow
• CPC Class Codes: G01N 33/558 using diffusion or migration of antigen or antibody immunochromatographic test strips G01N33/54387
• CPC Class Codes: G01N 33/6887 from muscle, cartilage or connective tissue

Abstract

Device including migration membrane, conjugate pad on migration membrane, plasma separation membrane on conjugate pad, pre-filter on plasma separation membrane. Migration membrane has test line configured for loading one or plurality of capture antibodies having specific binding affinity for assay target. Migration membrane configured for allowing lateral flow of blood plasma or serum across migration membrane to test line. Conjugate pad configured for loading one or plurality of detection antibodies having specific binding affinity for assay target. Plasma separation membrane configured for allowing passage of blood plasma or serum and trapping erythrocytes. Pre-filter configured for loading assay sample including erythrocytes and either or both blood plasma and blood serum. Pre-filter configured for allowing passage of blood plasma or serum through pre-filter and causing lateral flow of blood plasma or serum within pre-filter. Method includes providing device and carrying out diagnostic assay cycle.

Claims

1. A device, comprising:

a migration membrane, having a test line configured for loading onto the test line of one or a plurality of capture antibodies having specific binding affinity for an assay target, the migration membrane being configured for allowing lateral flow of blood plasma or serum across the migration membrane to the test line;

a conjugate pad on the migration membrane, being configured for loading onto the conjugate pad of one or a plurality of detection antibodies having specific binding affinity for an assay target;

a plasma separation membrane on the conjugate pad, the plasma separation membrane being configured for allowing passage of blood plasma or serum through the plasma separation membrane and for trapping erythrocytes; and

a pre-filter on the plasma separation membrane, the pre-filter being configured for loading of an assay sample including erythrocytes and either or both of blood plasma and blood serum onto the pre-filter, the pre-filter being configured for allowing passage of blood plasma or serum through the pre-filter and configured for causing lateral flow of blood plasma or serum within the pre-filter.

2. The device of claim 1, wherein the plasma separation membrane has a first surface facing toward the pre-filter and a second surface facing toward the conjugate pad, wherein the plasma separation membrane includes a plurality of passageways each communicating with both of the first and second surfaces, and wherein a plurality of the passageways each has a first opening at the first surface and a second opening at the second surface, the second opening being smaller than the first opening.

3. The device of claim 2, wherein each of a plurality of the passageways has a frustoconical shape, the plurality of passageways being laterally spaced apart from each other within the plasma separation membrane.

4. The device of claim 3, wherein the frustoconical shape of each of the plurality of passageways is configured for trapping and immobilizing erythrocytes.

5. The device of claim 1, wherein the pre-filter has a random structure configured for allowing omnidirectional passage of blood plasma or serum through the pre-filter.

6. The device of claim 1, wherein the pre-filter has a random fibrous structure.

7. The device of claim 1, wherein the pre-filter is configured for causing selective passage of blood plasma or serum through the pre-filter and for trapping erythrocytes.

8. The device of claim 7, wherein the pre-filter is configured for trapping at least about 10% of a quantity of erythrocytes from an assay sample.

9. The device of claim 1, wherein the pre-filter has an exposed first surface and a second surface facing toward the plasma separation membrane, wherein the pre-filter has an asymmetric structure including a plurality of passageways each having a first opening communicating with the first surface and a second opening communicating with the second surface, and wherein an average spacing between the second openings is larger than an average spacing between the first openings.

10. The device of claim 1, wherein the pre-filter and the plasma separation membrane are collectively configured for trapping at least about 90% of a quantity of erythrocytes from an assay sample.

11. The device of claim 1, wherein the device is configured for conveying between about 60% by volume and about 80% by volume of the blood plasma or serum from an assay sample to the migration membrane.

12. The device of claim 11, including configuring the device as capable of utilizing a single drop of whole blood as the assay sample.

13. The device of claim 1, wherein the migration membrane has a longitudinal axis, wherein the plasma separation membrane has a midpoint tangentially located over a first point along the longitudinal axis, wherein the conjugate pad has a midpoint tangentially located over a second point along the longitudinal axis, and wherein the second point is nearer to the test line than is the first point.

14. The device of claim 1, wherein the detection antibodies include a bound visibly colored agent, and wherein the migration membrane is configured for causing a leading edge of the visibly colored agent to be conveyed across the migration membrane at a controlled speed within a range of between about 2.5 minutes per 3 centimeters and about 3.75 minutes per 3 centimeters.

15. The device of claim 14, wherein the migration membrane is impregnated with a membrane blocking buffer at a concentration selected for causing blood plasma or serum to be conveyed at the controlled speed.

16. The device of claim 14, wherein the migration membrane has an average pore diameter selected for causing blood plasma or serum to be conveyed at the controlled speed.

17. The device of claim 14, wherein the migration membrane is electrically uncharged.

18. The device of claim 1, wherein the one detection antibody has or the plurality of detection antibodies have specific binding affinity for a cardiac Troponin-I epitope.

19. The device of claim 18, wherein the plurality of detection antibodies includes cardiac Troponin-I antibody clone 19C7 together with either or both of cardiac Troponin-I antibody clones 4C2 and M155.

20. The device of claim 1, wherein the device includes one or a plurality of capture antibodies on the test line having specific binding affinity for a cardiac Troponin-I epitope.

21. The device of claim 20, wherein the plurality of capture antibodies includes cardiac Troponin-I antibody clone MF4 and cardiac Troponin-I antibody clone 16A11.

22. The device of claim 1, wherein the device includes first and second detection antibodies on the conjugate pad, wherein the device includes third and fourth capture antibodies on the test line, and wherein each of the first, second, third and fourth antibodies has specific binding affinity for a substantially different cardiac Troponin-I epitope.

23. The device of claim 22, wherein the first antibody is cardiac Troponin-I antibody 19C7, the second antibody is selected from cardiac Troponin-I antibody clones 4C2 and M155, the third antibody is cardiac Troponin-I antibody clone MF4, and the fourth antibody is cardiac Troponin-I antibody clone 16A11.

24. A method, comprising:

providing a lateral-flow immuno-chromatographic assay device including a migration membrane, a conjugate pad being on the migration membrane, a plasma separation membrane being on the conjugate pad, and a pre-filter being on the plasma separation membrane;

wherein the conjugate pad is loaded with one or a plurality of detection antibodies having specific binding affinity for an assay target; and

wherein the migration membrane has a test line loaded with one or a plurality of capture antibodies having specific binding affinity for the assay target; and

carrying out a diagnostic assay cycle, including;

loading an assay sample including erythrocytes and either or both of blood plasma and blood serum onto the pre-filter;

causing blood plasma or serum to laterally flow within the pre-filter and allowing blood plasma or serum to pass through the pre-filter to the plasma separation membrane;

causing erythrocytes to be trapped in the plasma separation membrane and allowing blood plasma or serum to pass through the plasma separation membrane to the conjugate pad; and

allowing blood plasma or serum to pass through the conjugate pad onto the migration membrane and allowing blood plasma or serum to laterally flow across the migration membrane to the test line.

25. The method of claim 24, including causing erythrocytes to be trapped on the pre-filter and causing blood plasma or serum to selectively pass through the pre-filter.

26. The method of claim 24, including loading a chase buffer onto the pre-filter after loading the assay sample onto the pre-filter, and causing the chase buffer to enhance lateral flow of blood plasma or serum across the migration membrane to the test line.

27. The method of claim 24, wherein the detection antibodies include a bound visibly colored agent, and wherein allowing blood plasma or serum to laterally flow across the migration membrane to the test line includes causing a leading edge of the visibly colored agent to be conveyed across the migration membrane at a controlled speed within a range of between about 2.5 minutes per 3 centimeters and about 3.75 minutes per 3 centimeters.

28. The method of claim 24, wherein the one or plurality of detection antibodies have, and wherein the one or plurality of capture antibodies have, specific binding affinity for a cardiac Troponin-I epitope.

29. The method of claim 28, wherein the plurality of detection antibodies includes cardiac Troponin-I antibody clone 19C7 together with either or both of cardiac Troponin-I antibody clones 4C2 and M155.

30. The method of claim 28, wherein the plurality of capture antibodies includes cardiac Troponin-I antibody clones MF4 and 16A11.

31. The method of claim 27, wherein providing the lateral-flow immuno-chromatographic assay device includes loading first and second detection antibodies onto the conjugate pad and loading third and fourth capture antibodies onto the test line;

and wherein each of the first, second, third and fourth antibodies has specific binding affinity for a substantially different cardiac Troponin-I epitope.

32. The method of claim 31, wherein the first antibody is cardiac Troponin-I antibody clone 19C7, the second antibody is selected from cardiac Troponin-I antibody clones 4C2 and M155, the third antibody is cardiac Troponin-I antibody clone MF4, and the fourth antibody is cardiac Troponin-I antibody clone 16A11.

33. The method of claim 24, wherein the assay sample includes whole blood.

34. The method of claim 33, wherein the assay sample is a single drop of whole blood.

35. The method of claim 33, wherein the method includes collecting the whole blood from a human patient suspected of recently having suffered from or suspected of currently suffering from a myocardial infarction.

36. The method of claim 35, including collecting another assay sample including whole blood from the human patient, providing another lateral-flow immuno-chromatographic assay device, and utilizing the other assay sample and the other lateral-flow immuno-chromatographic assay device for carrying out another diagnostic assay cycle.